Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind study of oral hoslabconazole for tinea pedis
jRCT2031240672Active, not recruiting
- Sponsor
- Sato Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Athlete's foot comparing Hoslabconazole 100 mg with Placebo (2 arms). Primary endpoint: Cure rate at 12 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
hoslabconazole
03
Conditions
Athlete's foot
Beyond the preview
Go deeper on jRCT2031240672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240672.